Evidence map›Paper›PMID 32504414›Full record

ArticleMolecular diagnosis & therapy2020

Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules.

Erika F Rodriguez, Li-Hui Tseng, Federico De Marchi, Jialing Haung, Deborah Belchis, Rena Xian, Christopher D Gocke, James R Eshleman, Peter B Illei, Ming-Tseh Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Erika F RodriguezDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA. erodri17@jhmi.edu.
Li-Hui TsengDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Federico De MarchiDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Jialing HaungDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Deborah BelchisDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Rena XianDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Christopher D GockeDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
James R EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Peter B IlleiDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Ming-Tseh LinDepartment of Pathology, Johns Hopkins University School of Medicine, Carnegie 469, Pathology, 600 North Wolfe Street, Baltimore, MD, 21287, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferentiation between intrapulmonary metastasis (IPM) and multiple primary lung cancers (MPLC) in patients with synchronous or metachronous lung tumor nodules is critical but challenging.

objectiveWe proposed an algorithm to evaluate clonal origin based on trunk (initiating) versus branching drivers and the prevalence of mutations in lung adenocarcinomas.

methodsDriver mutations were examined using next-generation sequencing in five trunk driver genes (BRAF, EGFR, ERBB2, KRAS, and NRAS) and three branching driver genes (ATK1, PIK3CA, and TP53).

resultsMutational profiling supported same clonality and likely same clonality, respectively, in 39 and 14 of 66 pairs of specimens with known identical clonal origin. Discordance of TP53 mutations (branching drivers) was observed in three pairs. Subsequent analyses of 30 pairs of synchronous or metachronous lung tumor nodules revealed different clonality and likely different clonality in 17 and 2 pairs, respectively, including three pairs with similar histomorphology; same clonality and likely same clonality in three and five pairs, respectively, including two pairs with different histomorphology; and inconclusive or noninformative results in three pairs.

conclusionWhile discordance of trunk drivers indicated MPLC in patients with synchronous or metachronous lung tumor nodules, discordance of branching drivers did not exclude IPM. Concordance of uncommon drivers supported IPM, whereas concordance of common drivers did not exclude MPLC. Additional recommendations from official organizations are needed to guide applications of molecular markers in defining clonality of multiple lung tumor nodules.

Indexed as

AdenocarcinomaGenesHigh-Throughput Nucleotide SequencingHumansLung NeoplasmsMutationPrevalenceTumor Suppressor Protein p53Tumor Suppressor Protein p53

Identifiers

PMID32504414
OpenAlexW3033871179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.